Competitive GnRH receptor antagonist. Immediate suppression of LH surge without the agonist flare.
Reference facts
- Also known as
- Cetrotide
- Category
- GnRH & Reproductive
- Mechanism of action
- Competitive GnRH receptor antagonist. Immediate suppression of LH surge without the agonist flare.
- Targets
- GnRH receptor (antagonist)
- Indications under research or approved
- Prevention of premature LH surge during controlled ovarian stimulation in IVF
- Regulatory status (reference entry)
- FDA-approved (2000)
- Half-life
- ~30 hours (3 mg dose)
- Sequence notes
- Decapeptide GnRH antagonist Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2.
- Molecular weight (Da)
- 1431
- Originator / sponsor
- Merck Serono / EMD Serono
- First reported
- 1991
Primary References
Explore research articles about Cetrorelix
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.